CA2934453A1 - Compositions et methodes destinees a traiter le glaucome - Google Patents

Compositions et methodes destinees a traiter le glaucome Download PDF

Info

Publication number
CA2934453A1
CA2934453A1 CA2934453A CA2934453A CA2934453A1 CA 2934453 A1 CA2934453 A1 CA 2934453A1 CA 2934453 A CA2934453 A CA 2934453A CA 2934453 A CA2934453 A CA 2934453A CA 2934453 A1 CA2934453 A1 CA 2934453A1
Authority
CA
Canada
Prior art keywords
concentration
pharmaceutical composition
buffer
dexmedetomidine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2934453A
Other languages
English (en)
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GNT LLC
Original Assignee
GNT LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/132,780 external-priority patent/US20140107173A1/en
Application filed by GNT LLC filed Critical GNT LLC
Publication of CA2934453A1 publication Critical patent/CA2934453A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2934453A 2013-12-18 2014-02-11 Compositions et methodes destinees a traiter le glaucome Abandoned CA2934453A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/132,780 2013-12-18
US14/132,780 US20140107173A1 (en) 2011-02-03 2013-12-18 Compositions and Methods for Treatment of Glaucoma
PCT/US2014/015797 WO2015094392A1 (fr) 2013-12-18 2014-02-11 Compositions et méthodes destinées à traiter le glaucome

Publications (1)

Publication Number Publication Date
CA2934453A1 true CA2934453A1 (fr) 2015-06-25

Family

ID=53403464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934453A Abandoned CA2934453A1 (fr) 2013-12-18 2014-02-11 Compositions et methodes destinees a traiter le glaucome

Country Status (7)

Country Link
EP (1) EP3082427A4 (fr)
JP (1) JP2017501224A (fr)
CN (1) CN106455567A (fr)
BR (1) BR112016014404A2 (fr)
CA (1) CA2934453A1 (fr)
MX (1) MX2016007902A (fr)
WO (1) WO2015094392A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3429584A4 (fr) * 2016-03-17 2019-11-13 Presbyopia Therapies, LLC Compositions et méthodes de traitement de la presbytie
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2020259440A1 (fr) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 Pulvérisation nasale de dexmédétomidine, son procédé de préparation et son utilisation
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN118217243A (zh) * 2021-03-29 2024-06-21 四川普锐特药业有限公司 一种增效防腐且兼顾低刺激性的右美托咪定鼻喷剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
DK1654002T4 (da) * 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
EP2320911B1 (fr) * 2008-08-01 2014-10-08 Eye Therapies LLC Compositions de vasoconstriction, et procédés d'utilisation
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
WO2011075621A1 (fr) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions et méthodes d'administration ophtalmique de décongestionnants nasals
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
CN102883708A (zh) * 2010-04-07 2013-01-16 阿勒根公司 用于眼用组合物的防腐剂联合
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
US20140107173A1 (en) * 2011-02-03 2014-04-17 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
US20130172357A1 (en) * 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
EP2731606A1 (fr) * 2011-07-14 2014-05-21 Allergan, Inc. Compositions de gel d'oxymétazoline et leurs procédés d'utilisation
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
WO2013115844A1 (fr) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions et méthodes destinées à traiter le glaucome
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
JP2017501224A (ja) 2017-01-12
MX2016007902A (es) 2016-10-28
BR112016014404A2 (pt) 2017-08-08
CN106455567A (zh) 2017-02-22
EP3082427A4 (fr) 2017-08-02
WO2015094392A1 (fr) 2015-06-25
EP3082427A1 (fr) 2016-10-26

Similar Documents

Publication Publication Date Title
US8445526B2 (en) Compositions and methods for treatment of glaucoma
US20140163080A1 (en) Compositions and Methods for Treatment of Glaucoma
AU2008354558B2 (en) Stable ophthalmic formulations
US20140378401A1 (en) Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US20130172357A1 (en) Compositions and Methods for Treatment of Glaucoma
CA2934453A1 (fr) Compositions et methodes destinees a traiter le glaucome
KR20130112728A (ko) 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템
US20120309720A1 (en) Compositions and methods for treatment of glaucoma
KR20140056280A (ko) 비마토프로스트 및 브리모니딘의 고정된 용량 조합
US20140107173A1 (en) Compositions and Methods for Treatment of Glaucoma
US8999938B2 (en) Ophthalmic lipophilic drug delivery vehicle formulations
JP2017503028A (ja) 眼内血管新生及び／または漏出を治療するための組成物及び方法
CA2826644A1 (fr) Compositions et procedes pour le traitement du glaucome
CA2863760A1 (fr) Compositions et methodes destinees a traiter le glaucome
JP2016041738A (ja) 点眼用水性組成物
US20120202864A1 (en) Compositions and Methods for Treatment of Glaucoma
US20170143676A1 (en) Compositions and Methods for Treatment of Glaucoma
US20170224827A1 (en) Stable preservative free ophthalmic formulations of opioid antagonists
JP7534129B2 (ja) 多成分配合点眼剤
KR102444571B1 (ko) 세티리진 및 토코페솔란을 포함하는 안과용 조성물
JP7459508B2 (ja) ムチン変性抑制剤及び眼科用組成物
RU2772230C2 (ru) Композиция в форме глазных капель для снижения внутриглазного давления
WO2023152644A1 (fr) Composition pharmaceutique de lifitegrast et d'étabonate de lotéprednol
KR20230131822A (ko) 저장 안정성 안약을 위한 조성물 및 방법

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190212